Related Experiment Video
Updated: Aug 20, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study
Rutger Goekoop1, Serge A R B Rombouts, Cees Jonker
1Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands. R.Goekoop@vumc.nl
Abstract:
Mild cognitive impairment (MCI) often represents an early form of Alzheimer disease (AD). In both MCI and AD, characteristic cholinergic changes may occur. Functional magnetic resonance imaging (fMRI) may help to examine neurochemical changes in early disease by studying signal reactivity to pharmacological challenge. In this study, MCI patients [n=28; mean age 73.6+/-7.5; mini mental state examination (MMSE) 27.0+/-1.2] were scanned during task performance in a randomized trial under three different medication regimes: at baseline [BL; no galantamine (GAL)], after a single oral dose of GAL (SD), and after prolonged exposure (steady state: SS). Memory tasks included an episodic face-encoding task and a parametric n-letter back working memory (WM) task. Alterations in brain activation patterns before and after treatment were analyzed for both tasks using multilevel statistical analysis. Significant increases in brain activation from BL were observed after prolonged exposure only. For face encoding (n=28), these involved left prefrontal areas, the anterior cingulate gyrus, left occipital areas, and left posterior hippocampus. For working memory (n=28), increased activation was found in right precuneus and right middle frontal gyrus, coinciding with increased accuracy scores after GAL treatment. In conclusion, cholinergic challenge produces alterations in brain activation patterns in elderly MCI patients that can be detected with fMRI. This should encourage further functional imaging studies to examine the status of neurotransmitter systems in disease.
Insights
Functional magnetic resonance imaging (fMRI) detected changes in brain activation in mild cognitive impairment (MCI) patients after galantamine treatment. This suggests fMRI can reveal neurochemical system status in early Alzheimer disease (AD).
Area of Science:
- Neuroscience
- Pharmacology
- Medical Imaging
Background:
- Mild cognitive impairment (MCI) is an early sign of Alzheimer disease (AD), often involving cholinergic system changes.
- Functional magnetic resonance imaging (fMRI) can assess neurochemical alterations via pharmacological challenge.
Purpose of the Study:
- To investigate brain activation changes in MCI patients using fMRI under different galantamine (GAL) dosages.
- To examine the effects of GAL on memory task performance and associated neural activity.
Main Methods:
- A randomized trial involving 28 MCI patients scanned using fMRI under three conditions: baseline, single-dose GAL, and steady-state GAL.
- Memory tasks included episodic face encoding and an n-back working memory task.
- Multilevel statistical analysis was used to compare brain activation patterns.
Main Results:
- Prolonged GAL exposure significantly increased brain activation in MCI patients compared to baseline.
- Specific areas showing increased activation included the prefrontal cortex, anterior cingulate, occipital cortex, and hippocampus for face encoding.
- Working memory task performance and accuracy improved with GAL treatment, correlated with increased activation in the precuneus and middle frontal gyrus.
Conclusions:
- Cholinergic challenge with GAL alters brain activation patterns in MCI patients, detectable by fMRI.
- fMRI is a viable tool for studying neurotransmitter system status in early-stage neurodegenerative diseases like AD.
- Further research using functional imaging is warranted to explore neurotransmitter systems in disease states.
More Related Videos
11:27The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
Published on: April 25, 2012
14:47Combined Peripheral Nerve Stimulation and Controllable Pulse Parameter Transcranial Magnetic Stimulation to Probe Sensorimotor Control and Learning
Published on: April 21, 2023
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Treatment